Zentek Ltd. (ZTEKF): Financial results for FY2027
Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze
How this was made
The 30-second read
Why it matters
The release emphasizes a strengthened balance sheet after May 2026 financing, reports cash and working capital at September 30, 2026, and ties reported profitability to a non-cash impairment reversal tied to an updated Albany PEA and FVLCD estimate.
Market read
Traders can reassess near-term liquidity and project de-risking progress using the disclosed cash/working-capital figures and the earnings bridge that separates non-cash impairment effects from operating performance.
What to watch
Working capital improved after the May 2026 financing, so the key risk is whether future ZenGUARD order growth and Albany de-risking can translate into cash generation before additional dilution.
Background
Zentek is an advanced materials IP commercialization company with platforms including ZenGUARD filters and the Albany Graphite Project; it also holds aptamer-based technologies via Triera Biosciences.
Ticker impact
Zentek reports Q2 FY2027 results with cash rising to $13.6M and a $19.7M non-cash Albany Graphite impairment reversal.
Likely modest positive bias as investors focus on improved liquidity and progress toward Albany and ZenGUARD commercialization, offset by ongoing operating losses.
The filing provides concrete liquidity metrics (cash and working capital) and a clear bridge from net income to loss excluding the non-cash reversal, which should shape near-term sentiment.
Market effects
Highlights ongoing financing and de-risking dynamics for small-cap advanced materials and graphite development stories.
Relevant to Canadian micro/small-cap investors tracking TSXV/OTCQX issuers’ liquidity and project milestones.
Limited beyond niche commodity/materials and specialty filtration technology investor communities.
Counterpoint
The headline net income is largely driven by a non-cash impairment reversal, while operating expenses and cash burn indicate the core business still needs execution and funding.
Key entities
- companyZentek Ltd.
Reports Q2 FY2027 results, cash and working capital improvement, and an impairment reversal related to the Albany Graphite Project.
- assetAlbany Graphite Project
100% owned project in Northern Ontario; impairment reversal recognized after updated PEA and mineral resource estimate.
- product_platformZenGUARD™
Specialty coating for filters and PPE; management cites selling in Canada and the United States and ongoing order growth.



